Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 20 2024
0mins
Source: Benzinga
Aadi Bioscience's Licensing Agreement: Aadi Bioscience has entered into an exclusive license agreement with WuXi Biologics and Hangzhou DAC Biotechnology for the development of three preclinical antibody-drug conjugates, involving upfront payments of $44 million and potential milestone payments totaling up to $805 million.
Stock Performance and Recent Trial Halt: Following the announcement, AADI stock rose by 24.1% to $2.87, despite the company recently halting its PRECISION1 trial due to insufficient efficacy data for accelerated approval.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
